Clinical trials: Interventional Cardiology
Aortic Aneurysm
ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)
The ANCHOR registry is a multi-center, post-market, non-interventional, non-randomized, prospective study. Subjects must sign an ICF prior to obtaining any study specific information.
- Trial name
- ANCHOR (NCT01534819)
- Testing
- EndoAnchor™, endovascular treament
- Where
- 87 sites in United States, Australia and 11 more
- Volunteers
- 1,090 people
- Sponsor
- Medtronic Cardiovascular
Atrial Fibrillation, Maze Procedure
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
The primary objective of this Pivotal study is to demonstrate the safety and effectiveness of the Pulse Biosciences nsPFA™ Cardiac Surgery System in treating atrial fibrillation during concomitant cardiac surgical procedures.
- Conditions
- Atrial Fibrillation, Maze Procedure, AF, Ablation
- Trial name
- NANOCLAMP-AF (NCT06959121)
- Testing
- CellFX® nsPFA™ Cardiac Surgery System
- Where
- 3 sites in United States
- Volunteers
- 135 people
- Sponsor
- Pulse Biosciences, Inc.
Atherosclerotic Cardiovascular Disease
Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia
This study is an open label, randomized, prospective, type I hybrid effectiveness- implementation, pragmatic clinical trial to evaluate the impact of a targeted lipid optimization program on LDL-C control in participants with…
- Trial name
- OPTIMA (NCT07034690)
- Testing
- Educational Material, Standard of care
- Where
- United Arab Emirates
- Volunteers
- 326 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Foot Ulcer
Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers
The purpose of this study is to determine safety and efficacy of a new gel formulation of Esmolol hydrochloride (Galnobax®) for the treatment of Diabetic Foot Ulcer (DFU).
- Trial name
- NCT01113515
- Testing
- Esmolol hydrochloride
- Where
- 5 sites in United States, India and 1 more
- Volunteers
- 44 people
- Sponsor
- Novalead Pharma Private Limited
Hypertension
Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients
Open-label, inteRventional clinical Trial to assess EffIcacy and safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients.
- Trial name
- ARTEMISIA (NCT06104423)
- Testing
- Nebivolol 5 mg, Ramipril 2.5/5/10 mg
- Where
- Hungary
- Volunteers
- 266 people
- Sponsor
- Menarini International Operations Luxembourg SA
Hypertension
Effectiveness and Safety of Combination of Amlodipine and Zofenopril in Hypertensive Patients Versus Each Monotherapy
Study to assess the anti-hypertensive efficacy and safety of the extemporaneous combination of Zofenopril 30 mg in combination with Amlodipine 5 mg or AML 10 mg in lowering the sitting diastolic BP after 8 weeks of treatment in…
- Trial name
- Masolino (NCT05279807)
- Testing
- Zofenopril, Amlodipine
- Where
- Hungary
- Volunteers
- 277 people
- Sponsor
- Menarini International Operations Luxembourg SA
Coronary Artery Disease
FAME II-10-year Follow-Up
The FAME-II trial was a prospective, multicenter, multinational, multi-continental, randomized clinical trial with an 'all comers' design.
- Trial name
- FAME2-10yFU (NCT06159231)
- Where
- 16 sites in United States, Belgium and 9 more
- Volunteers
- 888 people
- Sponsor
- CoreAalst BV
Myocardial Infarction
A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
The purpose of this study is to determine whether abciximab given in combination with reteplase, before patients have a coronary intervention (a standard treatment where a catheter is inserted into the heart artery to get blood…
- Trial name
- NCT00046228
- Where
- 227 sites in United States, Argentina and 17 more
- Volunteers
- 2,461 people
- Sponsor
- Centocor, Inc.
Atrial Fibrillation
SOLAR & ATRILAZE Atrial Fibrillation Trial
The purpose of study is to conduct a pivotal evaluation of the EndoPhotonix™ SOLAR™ System and ATRILAZE™ System in order to obtain a labeling claim on the devices for the treatment of atrial fibrillation.
- Trial name
- SAAF-T (NCT00734058)
- Testing
- Laser MAZE by Ablation of Cardiac Tissue
- Volunteers
- 90 people
- Sponsor
- EndoPhotonix, Inc.
Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice
The study will provide information on outcomes in people with multiple myeloma, or systemic AL amyloidosis, or both, under standard care. AL is short for amyloid light-chain.
- Trial name
- DOrianT (NCT04659798)
- Where
- 14 sites in Spain
- Volunteers
- 240 people
- Sponsor
- Takeda
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Coronary Disease
Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety
This trial aims to demonstrate the non-inferiority of the CI-CMS-005 Coronary Stent System to the study device as well as to the TAXUS™ Express2™ Drug-Eluting Coronary Stent System in in-segment late lumen loss at 9 months after…
- Trial name
- NCT00415961
- Testing
- CoStar Paclitaxel Drug-Eluting Coronary Stent System
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Conor Medsystems
High Risk PCI, Coronary Arterial Disease (CAD)
Prospective Evaluation for Receiving SynFlow 3.0 Interventional Circulatory Support in High-risk PCI: A Randomized Controlled Trial
This study is conducted to compare the effectiveness of a new percutaneous mechanical circulatory support device called SynFlow 3.0 with VA-ECMO in high-risk percutaneous coronary intervetnion(PCI) patients.
- Trial name
- PERSIST Ⅲ (NCT06853470)
- Testing
- VA-ECMO circulatory support, SynFlow 3.0 circulatory support, percutaneous coronary intervention
- Where
- China
- Volunteers
- 222 people
- Sponsor
- ForQaly Medical (Shanghai) Co., Ltd
Arrhythmia
Electrocardiogram (ECG) Recordings in Paediatric Population
The primary goal of this protocol is to collect ECG signals from paediatric patients using 4 surface electrodes placed in the configurations proposed for the Cameron Health, Inc.
- Trial name
- NCT00399386
- Testing
- EP, ICD, Ablation
- Where
- United Kingdom
- Volunteers
- 62 people
- Sponsor
- Boston Scientific Corporation
Stable Angina Pectoris, Atherosclerosis
Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina Pectoris
Molsidomine used as an add-on treatment on standard care therapy should be superior to placebo used also as an add-on treatment on standard care therapy on improving the endothelial function (endothelium score measured by…
- Trial name
- MEDCOR (NCT01363661)
- Testing
- Coruno
- Where
- Belgium
- Volunteers
- 165 people
- Sponsor
- Therabel Pharma SA/NV
Fabry Disease
Home Therapy With Replagal in Fabry Disease
The purpose of this study is to proof increasing patient satisfaction and preservation of quality of life in patients with Morbus Fabry disease receiving their Enzyme Replacement Therapy with Replagal (Agalsidase alfa) at home…
- Trial name
- NCT01355146
- Where
- 22 sites in Austria, Germany
- Volunteers
- 127 people
- Sponsor
- Shire
Blood Loss, Surgical
Evaluation of the Clinical Performance of the Quantra System With the Quantra Surgical Cartridge
This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the Quantra Surgical Cartridge in patients undergoing major surgical procedures specifically, major cardiac and…
- Trial name
- NCT03152461
- Testing
- Quantra System
- Where
- 4 sites in United States
- Volunteers
- 302 people
- Sponsor
- HemoSonics LLC
Diabetic Foot Ulcer, Venous Leg Ulcer
DETEC® Esterase for Screening Wound Infection at Point of Care
This non-interventional, single-blinded, prospective, observational study assesses the planar distribution of leukocyte esterase in wounds by placing wound exudates soaked wound dressings in the DETEC® Esterase device during…
- Conditions
- Diabetic Foot Ulcer, Venous Leg Ulcer, Pressure Ulcer
- Trial name
- NCT04614870
- Testing
- DETEC® Esterase
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Progenitec Inc.
Plasma Cell Myeloma
A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Primary Objective: To assess the effectiveness, in terms of overall response rate (ORR) of isatuximab patients with RRMM in routine clinical practice, within 12 months To assess other effectiveness parameters such as progression…
- Trial name
- IONA-MM (NCT04458831)
- Testing
- isatuximab SAR650984, Pomalidomide, Dexamethasone
- Where
- 129 sites in United States, Argentina and 19 more
- Volunteers
- 583 people
- Sponsor
- Sanofi